

# Evgeny N Imyanitov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9350254/publications.pdf>

Version: 2024-02-01

174  
papers

7,745  
citations

76326

40  
h-index

64796

79  
g-index

174  
all docs

174  
docs citations

174  
times ranked

11606  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathology of Breast and Ovarian Cancers among <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Results from the Consortium of Investigators of Modifiers of <i>BRCA1/2</i> (CIMBA). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 134-147.	2.5	513
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Association of Type and Location of <i>BRCA1</i> and <i>BRCA2</i> Mutations With Risk of Breast and Ovarian Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1347.	7.4	390
4	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	21.4	356
5	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. <i>Nature Genetics</i> , 2017, 49, 1767-1778.	21.4	289
6	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
7	Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103194.	4.4	260
8	Genome-Wide Association Study in <i>BRCA1</i> Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk. <i>PLoS Genetics</i> , 2013, 9, e1003212.	3.5	244
9	Mutational spectrum in a worldwide study of 29,700 families with <i>BRCA1</i> or <i>BRCA2</i> mutations. <i>Human Mutation</i> , 2018, 39, 593-620.	2.5	224
10	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
11	Cancer progression and tumor cell motility are associated with the <i>FGFR4</i> Arg(388) allele. <i>Cancer Research</i> , 2002, 62, 840-7.	0.9	207
12	Common Breast Cancer Susceptibility Alleles and the Risk of Breast Cancer for <i>BRCA1</i> and <i>BRCA2</i> Mutation Carriers: Implications for Risk Prediction. <i>Cancer Research</i> , 2010, 70, 9742-9754.	0.9	169
13	EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1871, 29-39.	7.4	137
14	Breast cancer risk variants at 6q25 display different phenotype associations and regulate <i>ESR1</i> , <i>RMND1</i> and <i>CCDC170</i> . <i>Nature Genetics</i> , 2016, 48, 374-386.	21.4	125
15	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. <i>Nature Genetics</i> , 2020, 52, 56-73.	21.4	120
16	Mechanisms of acquired tumor drug resistance. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2019, 1872, 188310.	7.4	111
17	On the origin and diffusion of <i>BRCA1</i> c.5266dupC (5382insC) in European populations. <i>European Journal of Human Genetics</i> , 2011, 19, 300-306.	2.8	107
18	Bardet-Biedl Syndrome. <i>Molecular Syndromology</i> , 2016, 7, 62-71.	0.8	103

#	ARTICLE	IF	CITATIONS
19	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2009, 18, 4442-4456.	2.9	99
20	Molecular Diagnostics in Clinical Oncology. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 76.	3.5	93
21	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	5.0	88
22	High response rates to neoadjuvant platinum-based therapy in ovarian cancer patients carrying germ-line BRCA mutation. <i>Cancer Letters</i> , 2015, 369, 363-367.	7.2	82
23	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. <i>Genetics in Medicine</i> , 2020, 22, 1653-1666.	2.4	82
24	Novel ALK fusion partners in lung cancer. <i>Cancer Letters</i> , 2015, 362, 116-121.	7.2	75
25	Searching for cancer-associated gene polymorphisms: promises and obstacles. <i>Cancer Letters</i> , 2004, 204, 3-14.	7.2	71
26	High frequency of BRCA1 5382insC mutation in Russian breast cancer patients. <i>European Journal of Cancer</i> , 2006, 42, 1380-1384.	2.8	70
27	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. <i>Human Molecular Genetics</i> , 2011, 20, 3304-3321.	2.9	68
28	Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia. <i>Familial Cancer</i> , 2007, 6, 281-286.	1.9	67
29	Evidence against involvement of p53 polymorphism in breast cancer predisposition. <i>International Journal of Cancer</i> , 2003, 103, 431-433.	5.1	65
30	Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. <i>International Journal of Cancer</i> , 2002, 100, 557-564.	5.1	64
31	NBS1 657del5 mutation may contribute only to a limited fraction of breast cancer cases in Russia. <i>International Journal of Cancer</i> , 2005, 114, 585-589.	5.1	59
32	High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. <i>International Journal of Cancer</i> , 2012, 130, 2867-2873.	5.1	58
33	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. <i>Cancer Research</i> , 2018, 78, 5419-5430.	0.9	54
34	CYP19 gene polymorphism in endometrial cancer patients. <i>Journal of Cancer Research and Clinical Oncology</i> , 2001, 127, 135-138.	2.5	51
35	Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations. <i>Breast Cancer Research and Treatment</i> , 2014, 145, 553-562.	2.5	51
36	CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity. <i>Cancer Letters</i> , 2004, 207, 191-196.	7.2	49

#	ARTICLE	IF	CITATIONS
37	Detection of <i>EGFR</i> mutations and <i>EML4-ALK</i> rearrangements in lung adenocarcinomas using archived cytological slides. <i>Cancer Cytopathology</i> , 2013, 121, 370-376.	2.4	48
38	Family History, Genetic Testing, and Clinical Risk Prediction: Pooled Analysis of CHEK2*1100delC in 1,828 Bilateral Breast Cancers and 7,030 Controls. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 230-234.	2.5	47
39	PALB2 mutations in German and Russian patients with bilateral breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 126, 545-550.	2.5	47
40	Pattern of clinically relevant mutations in consecutive series of Russian colorectal cancer patients. <i>Medical Oncology</i> , 2013, 30, 686.	2.5	43
41	Gene polymorphisms, apoptotic capacity and cancer risk. <i>Human Genetics</i> , 2009, 125, 239-246.	3.8	42
42	Multigene sequencing reveals heterogeneity of NLRP12-related autoinflammatory disorders. <i>Rheumatology International</i> , 2018, 38, 887-893.	3.0	42
43	Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. <i>Journal of the National Cancer Institute</i> , 2011, 103, 105-116.	6.3	40
44	High Efficacy of First-Line Gefitinib in Non-Asian Patients with EGFR-Mutated Lung Adenocarcinoma. <i>Onkologie</i> , 2010, 33, 231-238.	0.8	39
45	CYP17 genetic polymorphism in endometrial cancer: are only steroids involved?. <i>Cancer Letters</i> , 2002, 180, 47-53.	7.2	38
46	Coding polymorphisms in Casp5, Casp8 and DR4 genes may play a role in predisposition to lung cancer. <i>Cancer Letters</i> , 2009, 278, 183-191.	7.2	37
47	Cytotoxic and targeted therapy for hereditary cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 17.	1.5	37
48	Distribution of FGFR2, TNRC9, MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus elderly tumor-free women. <i>Cancer Genetics and Cytogenetics</i> , 2010, 199, 69-72.	1.0	35
49	Drug therapy for hereditary cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2011, 9, 5.	1.5	35
50	Frequent loss of heterozygosity at 1p36 in ovarian adenocarcinomas but the gene encoding p73 is unlikely to be the target. <i>Oncogene</i> , 1999, 18, 4640-4642.	5.9	34
51	Molecular pathogenesis of bilateral breast cancer. <i>Cancer Letters</i> , 2003, 191, 1-7.	7.2	34
52	Non-founder BRCA1 mutations in Russian breast cancer patients. <i>Cancer Letters</i> , 2010, 298, 258-263.	7.2	34
53	Ovarian cancer susceptibility alleles and risk of ovarian cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers. <i>Human Mutation</i> , 2012, 33, 690-702.	2.5	34
54	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. <i>PLoS ONE</i> , 2015, 10, e0120020.	2.5	34

#	ARTICLE	IF	CITATIONS
55	CHEK2 1100delC mutation is frequent among Russian breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2006, 100, 99-102.	2.5	32
56	Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients. <i>Cancer Letters</i> , 2015, 359, 259-261.	7.2	32
57	High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 5.	1.5	31
58	High prevalence of GPRC5A germline mutations in BRCA1-mutant breast cancer patients. <i>International Journal of Cancer</i> , 2014, 134, 2352-2358.	5.1	31
59	Identification of novel hereditary cancer genes by whole exome sequencing. <i>Cancer Letters</i> , 2015, 369, 274-288.	7.2	31
60	Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer. <i>Molecular Diagnosis and Therapy</i> , 2016, 20, 401-406.	3.8	30
61	Platinum drugs and taxanes: can we overcome resistance?. <i>Cell Death Discovery</i> , 2021, 7, 155.	4.7	30
62	CYP17 polymorphism in the groups of distinct breast cancer susceptibility: comparison of patients with the bilateral disease vs. monolateral breast cancer patients vs. middle-aged female controls vs. elderly tumor-free women. <i>Cancer Letters</i> , 2000, 156, 45-50.	7.2	28
63	Rapid selection of BRCA1-proficient tumor cells during neoadjuvant therapy for ovarian cancer in BRCA1 mutation carriers. <i>Cancer Letters</i> , 2017, 397, 127-132.	7.2	28
64	Evidence for predictive role of BRCA1 and bTUBIII in gastric cancer. <i>Medical Oncology</i> , 2013, 30, 545.	2.5	26
65	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. <i>Breast Cancer Research</i> , 2015, 17, 61.	5.0	26
66	Agreement between PDL1 immunohistochemistry assays and polymerase chain reaction in non-small cell lung cancer: CLOVER comparison study. <i>Scientific Reports</i> , 2020, 10, 3928.	3.3	26
67	Expression of Caspase-3 and -7 Does Not Correlate with the Extent of Apoptosis in Primary Breast Carcinomas. <i>Cell Cycle</i> , 2002, 1, 326-331.	2.6	25
68	High level of miR-21, miR-10b, and miR-31 expression in bilateral vs. unilateral breast carcinomas. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 1049-1059.	2.5	25
69	BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment. <i>Investigational New Drugs</i> , 2015, 33, 1136-1143.	2.6	25
70	Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28220.	1.5	24
71	KIT mutations in Russian patients with mucosal melanoma. <i>Melanoma Research</i> , 2011, 21, 555-559.	1.2	23
72	Efficacy of immune checkpoint blockade in MUTYH-associated hereditary colorectal cancer. <i>Investigational New Drugs</i> , 2020, 38, 894-898.	2.6	23

#	ARTICLE	IF	CITATIONS
73	Molecular-based choice of cancer therapy: Realities and expectations. <i>Clinica Chimica Acta</i> , 2007, 379, 1-13.	1.1	22
74	Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10931.	4.1	22
75	“Comparison of extremes” approach provides evidence against the modifying role of NAT2 polymorphism in lung cancer susceptibility. <i>Cancer Letters</i> , 2005, 221, 177-183.	7.2	21
76	Evidence for microsatellite instability in bilateral breast carcinomas. <i>Cancer Letters</i> , 2000, 154, 9-17.	7.2	20
77	Development of breast tumors in CHEK2, NBN/NBS1 and BLM mutation carriers does not commonly involve somatic inactivation of the wild-type allele. <i>Medical Oncology</i> , 2014, 31, 828.	2.5	20
78	Evidence for clinical efficacy of mitomycin C in heavily pretreated ovarian cancer patients carrying germ-line BRCA1 mutation. <i>Medical Oncology</i> , 2014, 31, 199.	2.5	20
79	A novel approach for assessment of cancer predisposing roles of GSTM1 and GSTT1 genes: use of putatively cancer resistant elderly tumor-free smokers as the referents. <i>Lung Cancer</i> , 2004, 43, 259-266.	2.0	19
80	Neoadjuvant therapy: theoretical, biological and medical consideration. <i>Chinese Clinical Oncology</i> , 2018, 7, 55-55.	1.2	19
81	Combined CYP1A1/GSTM1 at-risk genotypes are overrepresented in squamous cell lung carcinoma patients but underrepresented in elderly tumor-free subjects. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 327-331.	2.5	18
82	Microsatellite instability analysis of bilateral breast tumors suggests treatment-related origin of some contralateral malignancies. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 133, 57-64.	2.5	18
83	High sensitivity of BRCA1-associated tumors to cisplatin monotherapy: report of two cases. <i>Cancer Genetics and Cytogenetics</i> , 2010, 197, 91-94.	1.0	18
84	Mixed epithelial/mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast in BRCA1 carrier. <i>Breast Cancer</i> , 2011, 18, 137-140.	2.9	18
85	Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors. <i>International Journal of Cancer</i> , 2020, 146, 1879-1888.	5.1	18
86	Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 229-235.	2.5	18
87	EGFR mutation in kidney carcinoma confers sensitivity to gefitinib treatment: A case report. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 548-550.	1.6	17
88	Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 675-683.	2.5	17
89	BRCA1-associated and sporadic ovarian carcinomas: outcomes of primary cytoreductive surgery or neoadjuvant chemotherapy. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 779-786.	2.5	17
90	Mechanisms of lung cancer. <i>Drug Discovery Today Disease Mechanisms</i> , 2005, 2, 213-223.	0.8	16

#	ARTICLE	IF	CITATIONS
91	Evaluating Cancer Epidemiologic Risk Factors Using Multiple Primary Malignancies. <i>Epidemiology</i> , 2010, 21, 366-372.	2.7	16
92	Complete Clinical Response of BRAF-Mutated Cholangiocarcinoma to Vemurafenib, Panitumumab, and Irinotecan. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 502-505.	1.3	16
93	Study of Selected BRCA1, BRCA2, and PIK3CA Mutations in Benign and Malignant Lesions of Anogenital Mammary-Like Glands. <i>American Journal of Dermatopathology</i> , 2017, 39, 358-362.	0.6	16
94	Detection of BRCA1 gross rearrangements by droplet digital PCR. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 765-770.	2.5	16
95	Detection of ALK rearrangements in 4002 Russian patients: The utility of different diagnostic approaches. <i>Lung Cancer</i> , 2017, 103, 17-23.	2.0	15
96	ATL. <i>International Journal of Gynecological Cancer</i> , 2018, 28, 1498-1506.	2.5	15
97	Lack of Response to Vemurafenib in Melanoma Carrying BRAF K601E Mutation. <i>Case Reports in Oncology</i> , 2019, 12, 339-343.	0.7	15
98	Mechanisms of breast cancer. <i>Drug Discovery Today Disease Mechanisms</i> , 2004, 1, 235-245.	0.8	14
99	Paired distribution of molecular subtypes in bilateral breast carcinomas. <i>Cancer Genetics</i> , 2011, 204, 96-102.	0.4	14
100	Variability in lung cancer response to ALK inhibitors cannot be explained by the diversity of ALK fusion variants. <i>Biochimie</i> , 2018, 154, 19-24.	2.6	14
101	Value of bilateral breast cancer for identification of rare recessive at-risk alleles: evidence for the role of homozygous GEN1 c.2515_2519delAAGTT mutation. <i>Familial Cancer</i> , 2013, 12, 129-132.	1.9	13
102	ATM mutation spectrum in Russian children with ataxia-telangiectasia. <i>European Journal of Medical Genetics</i> , 2020, 63, 103630.	1.3	13
103	BRCA1 4153delA founder mutation in Russian ovarian cancer patients. <i>Hereditary Cancer in Clinical Practice</i> , 2006, 4, 193.	1.5	12
104	Ovarian cancer patient with germline mutations in both BRCA1 and NBN genes. <i>Cancer Genetics and Cytogenetics</i> , 2008, 186, 122-124.	1.0	12
105	Use of elderly tumor-free subjects as a "supercontrol" for cancer epidemiological studies: pros and cons. <i>Mechanisms of Ageing and Development</i> , 2009, 130, 122-127.	4.6	12
106	Lung Carcinomas with EGFR Exon 19 Insertions Are Sensitive to Gefitinib Treatment. <i>Journal of Thoracic Oncology</i> , 2014, 9, e31-e33.	1.1	12
107	Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern Europe. <i>Familial Cancer</i> , 2015, 14, 145-149.	1.9	12
108	GSTM1 genotypes in elderly tumour-free smokers and non-smokers. <i>Lung Cancer</i> , 2000, 29, 189-195.	2.0	11

#	ARTICLE	IF	CITATIONS
109	Measurement of DPD and TS Transcripts Aimed to Predict Clinical Benefit from Fluoropyrimidines: Confirmation of the Trend in Russian Colorectal Cancer Series and Caution Regarding the Gene Referees. <i>Oncology Research and Treatment</i> , 2007, 30, 295-300.	1.2	11
110	Distribution of Coding Apoptotic Gene Polymorphisms in Women with Extreme Phenotypes of Breast Cancer Predisposition and Tolerance. <i>Tumori</i> , 2011, 97, 248-251.	1.1	11
111	Molecular predictors of the outcome of paclitaxel plus carboplatin neoadjuvant therapy in high-grade serous ovarian cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 439-450.	2.3	11
112	Cytotoxic and targeted therapy for BRCA1/2-driven cancers. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 36.	1.5	11
113	Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: Possible role of host factors and survival bias. <i>International Journal of Cancer</i> , 2007, 120, 297-302.	5.1	10
114	Molecular Tests for the Choice of Cancer Therapy. <i>Current Pharmaceutical Design</i> , 2017, 23, 4794-4806.	1.9	10
115	Comparative analysis of expression of mutant and wild-type alleles is essential for reliable PCR-based detection of MET exon 14 skipping. <i>Biochimie</i> , 2019, 165, 267-274.	2.6	10
116	Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab. <i>Case Reports in Oncology</i> , 2020, 13, 985-989.	0.7	10
117	Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1943-1953.	1.8	10
118	Next generation sequencing analysis of consecutive Russian patients with clinical suspicion of inborn errors of immunity. <i>Clinical Genetics</i> , 2020, 98, 231-239.	2.0	10
119	Searching for susceptibility alleles: Emphasis on bilateral breast cancer. <i>International Journal of Cancer</i> , 2007, 121, 921-923.	5.1	9
120	Breast cancer therapy for BRCA1 carriers: moving towards platinum standard?. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 8.	1.5	9
121	The spectrum of Lynch syndrome-associated germ-line mutations in Russia. <i>European Journal of Medical Genetics</i> , 2020, 63, 103753.	1.3	9
122	Exome sequencing study of Russian breast cancer patients suggests a predisposing role for USP39. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 731-742.	2.5	9
123	Frequency and molecular characteristics of PALB2-associated cancers in Russian patients. <i>International Journal of Cancer</i> , 2021, 148, 203-210.	5.1	9
124	Molecular testing for colorectal cancer: Clinical applications. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1288-1301.	2.0	9
125	Molecular tests for prediction of tumor sensitivity to cytotoxic drugs. <i>Cancer Letters</i> , 2022, 526, 41-52.	7.2	9
126	Exome Sequencing of a Family with Bardet-Biedl Syndrome Identifies the Common Russian Mutation c.1967_1968delTAinsC in <i>and BBS7</i> . <i>Molecular Syndromology</i> , 2015, 6, 96-98.	0.8	8



#	ARTICLE	IF	CITATIONS
145	Unusual Clinical Presentation of Gastrointestinal Clear Cell Sarcoma. <i>Gastrointestinal Tumors</i> , 2015, 2, 83-88.	0.7	5
146	BRAF and NRAS mutations in Russian melanoma patients: results of a nationwide study. <i>Melanoma Research</i> , 2016, 26, 442-447.	1.2	5
147	Highly Sensitive and Reliable Detection of EGFR Exon 19 Deletions by Droplet Digital Polymerase Chain Reaction. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 555-562.	3.8	5
148	Systemic investigations into the molecular features of bilateral breast cancer for diagnostic purposes. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 41-47.	3.1	5
149	Clinical case of the neoadjuvant treatment with nivolumab in a patient with microsatellite unstable (MSI-H) locally advanced gastric cancer. <i>BMJ Case Reports</i> , 2020, 13, e236144.	0.5	5
150	Content of circulating tumor DNA depends on the tumor type and the dynamics of tumor size, but is not influenced significantly by physical exercise, time of the day or recent meal. <i>Cancer Genetics</i> , 2021, 256-257, 165-178.	0.4	5
151	“Lazarus Response” to Olaparib in a Virtually Chemonaive Breast Cancer Patient Carrying Gross BRCA2 Gene Deletion. <i>Cureus</i> , 2018, 10, e2150.	0.5	5
152	PCR-based analysis of PD-L1 RNA expression in lung cancer: comparison with commonly used immunohistochemical assays. <i>Annals of Diagnostic Pathology</i> , 2022, 59, 151968.	1.3	5
153	Evidence for depletion of CASP5 Ala90Thr heterozygous genotype in aged subjects. <i>Experimental Gerontology</i> , 2010, 45, 726-729.	2.8	4
154	Evidence for angiogenesis-independent contribution of VEGFR1 (FLT1) in gastric cancer recurrence. <i>Medical Oncology</i> , 2013, 30, 644.	2.5	4
155	Neoadjuvant therapy of BRCA1-driven ovarian cancer by combination of cisplatin, mitomycin C and doxorubicin. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 14.	1.5	4
156	The frequency and spectrum of PIK3CA mutations in patients with estrogen receptor-positive HER2-negative advanced breast cancer residing in various regions of Russia. <i>Journal of Modern Oncology</i> , 2021, 23, 61-67.	0.3	4
157	Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib. <i>Neuro-Oncology</i> , 2022, 24, 1029-1031.	1.2	4
158	Large family with both parents affected by distinct BRCA1 mutations: implications for genetic testing. <i>Hereditary Cancer in Clinical Practice</i> , 2009, 7, 2.	1.5	3
159	Mitomycin C plus cisplatin for systemic treatment of recurrent BRCA1-associated ovarian cancer. <i>Investigational New Drugs</i> , 2020, 38, 1872-1878.	2.6	3
160	Small fraction of testicular cancer cases may be causatively related to CHEK2 inactivating germ-line mutations: evidence for somatic loss of the remaining CHEK2 allele in the tumor tissue. <i>Familial Cancer</i> , 2021, 20, 49-53.	1.9	3
161	Response to: The <i>GPRC5A</i> frameshift variant c.183del is not associated with increased breast cancer risk in <i>BRCA1</i> mutation carriers. <i>International Journal of Cancer</i> , 2019, 144, 1758-1760.	5.1	2
162	Harmonization of Molecular Testing for Non-Small Cell Lung Cancer: Emphasis on PD-L1. <i>Frontiers in Oncology</i> , 2020, 10, 549198.	2.8	2

#	ARTICLE	IF	CITATIONS
163	Multigene testing for breast cancer risk assessment: an illusion of added clinical value. <i>Chinese Clinical Oncology</i> , 2017, 6, 15-15.	1.2	2
164	Molecular diagnostics in oncology: new trends. <i>Meditinskii Akademicheskii Zhurnal</i> , 2019, 19, 25-32.	0.2	2
165	The frequency of the BLM* <i>p.Q548X (c.1642C&gt;A)</i> mutation in breast cancer patients from Russia. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 695-696.	2.5	1
166	Evidence for a pathogenic role of BRCA1 L1705P and W1837X germ-line mutations. <i>Molecular Biology Reports</i> , 2016, 43, 335-338.	2.3	1
167	Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine. <i>Hereditary Cancer in Clinical Practice</i> , 2021, 19, 2.	1.5	1
168	Tumor irradiation may facilitate the detection of tumor-specific mutations in plasma. <i>World Journal of Clinical Oncology</i> , 2021, 12, 1215-1226.	2.3	1
169	Preparation of Duplex Sequencing Libraries for Archival Paraffin-Embedded Tissue Samples Using Single-Strand-Specific Nuclease P1. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4586.	4.1	1
170	Molecular genetic testing in colon cancer: clinical aspects. <i>Al'manah Klinicheskoy Meditsiny</i> , 2022, 50, 1-12.	0.3	1
171	Integration of the blood test into the low-dose computed tomography lung cancer screening: reliable discrimination between malignant and non-malignant radiographic findings. <i>Translational Lung Cancer Research</i> , 2021, 10, 4035-4038.	2.8	0
172	Neoadjuvant therapy for ovarian cancer. <i>Chinese Clinical Oncology</i> , 2018, 7, 54-54.	1.2	0
173	Molecular genetic testing in colon cancer: clinical aspects. <i>Al'manah Klinicheskoy Meditsiny</i> , 0, , .	0.3	0
174	Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	2.2	0